Lung cancer immunotherapy is rapidly evolving beyond traditional checkpoint inhibitors to overcome resistance and treat more patients. New approaches focus on directly engaging immune cells and targeting multiple tumor pathways, improving effectiveness in both small cell and non-small cell lung cancer.
A major breakthrough is tarlatamab, the first BiTE approved for a solid tumor, which brings T cells into direct contact with cancer cells. Other bispecific antibodies like amivantamab target multiple proteins to overcome resistance. Personalized cancer vaccines and adoptive cell therapies, including CAR T-cells and tumor-infiltrating lymphocytes, further enhance immune precision and adaptability.
Additional advances include new checkpoint targets such as LAG-3 and TIGIT, along with antibody-drug conjugates targeting HER2 and MET. Combination strategies integrating immunotherapy with chemotherapy, radiation, and targeted drugs are expanding. Overall, lung cancer treatment is shifting toward personalized, multi-modal approaches for more durable responses.